Suchergebnis | Hamburg Open Science

Facetten

4 Einträge gefunden

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
2021 - Forschungsinformationssystem des UKE - frei zugänglich
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
2020 - Forschungsinformationssystem des UKE
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
2020 - Forschungsinformationssystem des UKE
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
2019 - Forschungsinformationssystem des UKE